An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Iktos announced a collaboration with Zealand Pharma (NASDAQ: ZEAL) to co-develop AI technologies for peptide drug design. This partnership leverages Iktos' machine learning capabilities and Zealand's expertise in peptide discovery. The collaboration aims to enhance drug discovery processes through Iktos’ state-of-the-art modeling technology, focusing on designing novel peptide therapeutics. Both companies are dedicated to improving the efficiency of drug development, with Zealand contributing its extensive knowledge in peptide drugs.
Positive
Collaboration with Iktos to co-develop AI technology for peptide drug design.
Zealand's expertise in peptide drug discovery enhances the collaboration's potential.
Negative
None.
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Collaboration leverages Iktos’ capabilities in machine learning and AI and Zealand expertise in peptide drug discovery
PARIS--(BUSINESS WIRE)--
Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design.
Iktos’ AI technology, based on a comprehensive data-driven chemical structure generation technology, brings new insights into the drug discovery process. This technology automatically designs virtual novel molecules with all the characteristics of a successful drug molecule. Iktos has recently diversified its R&D efforts into the development of an AI technology for peptide-based therapeutics and has developed state-of-the-art generative and predictive models to facilitate design of novel peptide therapeutics with desired properties.
Zealand Pharma A/S has a track record of successfully inventing and developing novel peptide-based drugs. This success is based on the extensive experience in improving the therapeutic characteristics of peptides. Zealand Pharma has a keen interest in expanding its computational chemistry toolbox to include AI and machine learning based approaches for the design of novel therapeutic peptides (https://www.zealandpharma.com/).
Under the agreement, Zealand will contribute its expertise in peptide drug discovery to Iktos’ generative modelling technologies and expertise in machine learning and AI.
“We are very pleased to join forces with Zealand Pharma and leverage their deep know-how in peptide therapeutics with our state-of-the-art existing technology assets to peptide drug discovery” commented Yann Gaston-Mathé, President and CEO of Iktos. “We look forward to working with Zealand’s experienced R&D team to build leading/state of the art peptide generative and predictive modelling technology in the field of peptides - a new area for Iktos.”
# # #
About IKTOS
Incorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya™. Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis. Iktos has recently diversified its R&D efforts into the development of an AI technology for peptide-based therapeutics and has developed state-of-the-art generative and predictive models to facilitate design of novel peptide therapeutics with desired properties.
What is the recent collaboration between Zealand Pharma and Iktos?
Zealand Pharma and Iktos are collaborating to develop AI technologies for peptide drug design, combining Iktos' machine learning capabilities with Zealand's drug discovery expertise.
What does Zealand Pharma aim to achieve with the AI collaboration?
Zealand Pharma aims to enhance its peptide drug discovery process by integrating advanced AI and machine learning approaches through its collaboration with Iktos.
How will the partnership with Iktos benefit Zealand Pharma?
The partnership will leverage Iktos' generative modeling technologies to improve the efficiency and effectiveness of peptide drug design for Zealand Pharma.
What is Zealand Pharma's stock symbol?
The stock symbol for Zealand Pharma is NASDAQ: ZEAL.
When was the collaboration between Zealand Pharma and Iktos announced?
